Cargando…

A Balanced Risk–Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)—The Case of Tea and Herbal Infusions

Humans are exposed to pyrrolizidine alkaloids (PA) through different sources, mainly from contaminated foodstuff. Teas and herbal infusions (T&HI) can be contaminated by PA producing weed. PA can possess toxic, mutagenic, genotoxic, and carcinogenic properties. Thus, possible health risks for th...

Descripción completa

Detalles Bibliográficos
Autores principales: Habs, Michael, Binder, Karin, Krauss, Stefan, Müller, Karolina, Ernst, Brigitte, Valentini, Luzia, Koller, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537832/
https://www.ncbi.nlm.nih.gov/pubmed/28686224
http://dx.doi.org/10.3390/nu9070717
_version_ 1783254255817195520
author Habs, Michael
Binder, Karin
Krauss, Stefan
Müller, Karolina
Ernst, Brigitte
Valentini, Luzia
Koller, Michael
author_facet Habs, Michael
Binder, Karin
Krauss, Stefan
Müller, Karolina
Ernst, Brigitte
Valentini, Luzia
Koller, Michael
author_sort Habs, Michael
collection PubMed
description Humans are exposed to pyrrolizidine alkaloids (PA) through different sources, mainly from contaminated foodstuff. Teas and herbal infusions (T&HI) can be contaminated by PA producing weed. PA can possess toxic, mutagenic, genotoxic, and carcinogenic properties. Thus, possible health risks for the general population are under debate. There is a strong safety record for T&HI and additionally epidemiological evidence for the preventive effects of regular tea consumption on cardiovascular events and certain types of cancer. There is no epidemiological evidence, however, for human risks of regular low dose PA exposure. Recommended regulatory PA-threshold values are based on experimental data only, accepting big uncertainties. If a general risk exists through PA contaminated T&HI, it must be small compared to other frequently accepted risks of daily living and the proven health effects of T&HI. Decision making should be based on a balanced riskbenefit analysis. Based on analyses of the scientific data currently available, it is concluded that the benefits of drinking T&HI clearly outweigh the negligible health risk of possible PA contamination. At the same time, manufacturers must continue their efforts to secure good product quality and to be transparent on their measures of quality control and risk communication.
format Online
Article
Text
id pubmed-5537832
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-55378322017-08-04 A Balanced Risk–Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)—The Case of Tea and Herbal Infusions Habs, Michael Binder, Karin Krauss, Stefan Müller, Karolina Ernst, Brigitte Valentini, Luzia Koller, Michael Nutrients Review Humans are exposed to pyrrolizidine alkaloids (PA) through different sources, mainly from contaminated foodstuff. Teas and herbal infusions (T&HI) can be contaminated by PA producing weed. PA can possess toxic, mutagenic, genotoxic, and carcinogenic properties. Thus, possible health risks for the general population are under debate. There is a strong safety record for T&HI and additionally epidemiological evidence for the preventive effects of regular tea consumption on cardiovascular events and certain types of cancer. There is no epidemiological evidence, however, for human risks of regular low dose PA exposure. Recommended regulatory PA-threshold values are based on experimental data only, accepting big uncertainties. If a general risk exists through PA contaminated T&HI, it must be small compared to other frequently accepted risks of daily living and the proven health effects of T&HI. Decision making should be based on a balanced riskbenefit analysis. Based on analyses of the scientific data currently available, it is concluded that the benefits of drinking T&HI clearly outweigh the negligible health risk of possible PA contamination. At the same time, manufacturers must continue their efforts to secure good product quality and to be transparent on their measures of quality control and risk communication. MDPI 2017-07-07 /pmc/articles/PMC5537832/ /pubmed/28686224 http://dx.doi.org/10.3390/nu9070717 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Habs, Michael
Binder, Karin
Krauss, Stefan
Müller, Karolina
Ernst, Brigitte
Valentini, Luzia
Koller, Michael
A Balanced Risk–Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)—The Case of Tea and Herbal Infusions
title A Balanced Risk–Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)—The Case of Tea and Herbal Infusions
title_full A Balanced Risk–Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)—The Case of Tea and Herbal Infusions
title_fullStr A Balanced Risk–Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)—The Case of Tea and Herbal Infusions
title_full_unstemmed A Balanced Risk–Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)—The Case of Tea and Herbal Infusions
title_short A Balanced Risk–Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)—The Case of Tea and Herbal Infusions
title_sort balanced risk–benefit analysis to determine human risks associated with pyrrolizidine alkaloids (pa)—the case of tea and herbal infusions
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537832/
https://www.ncbi.nlm.nih.gov/pubmed/28686224
http://dx.doi.org/10.3390/nu9070717
work_keys_str_mv AT habsmichael abalancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions
AT binderkarin abalancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions
AT kraussstefan abalancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions
AT mullerkarolina abalancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions
AT ernstbrigitte abalancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions
AT valentiniluzia abalancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions
AT kollermichael abalancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions
AT habsmichael balancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions
AT binderkarin balancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions
AT kraussstefan balancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions
AT mullerkarolina balancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions
AT ernstbrigitte balancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions
AT valentiniluzia balancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions
AT kollermichael balancedriskbenefitanalysistodeterminehumanrisksassociatedwithpyrrolizidinealkaloidspathecaseofteaandherbalinfusions